Sign up to save your podcasts
Or
Share Extending Horizons With Immune Checkpoint Inhibitors in Small Cell Lung Cancer: 2022 Perspectives
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Extending Horizons With Immune Checkpoint Inhibitors in Small Cell Lung Cancer: 2022 Perspectives
Patients with extensive-stage small cell lung cancer (ES-SCLC) have a 10-month survival of 10 months following standard frontline chemotherapy. Join the experts in discussing immune checkpoint inhibitors (ICIs) in patients with SCLC.
Credit available for this activity expires: 6/15/2023
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/975532?src=mkm_podcast_addon_975532
View all episodes
By Medscape Podcasts
4
77 ratings
Patients with extensive-stage small cell lung cancer (ES-SCLC) have a 10-month survival of 10 months following standard frontline chemotherapy. Join the experts in discussing immune checkpoint inhibitors (ICIs) in patients with SCLC.
Credit available for this activity expires: 6/15/2023
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/975532?src=mkm_podcast_addon_975532
More shows like Keeping Current
View all
NEJM This Week
320 Listeners
JAMA Clinical Reviews
497 Listeners
WSJ Tech News Briefing
1,639 Listeners
This Week in Cardiology
882 Listeners
The Bob Harrington Show
14 Listeners
One-on-One with Eric Topol
16 Listeners
Mayo Clinic Talks
292 Listeners
The Curbsiders Internal Medicine Podcast
3,347 Listeners
The Peter Attia Drive
8,521 Listeners
Annals On Call Podcast
193 Listeners
JAMA Medical News
92 Listeners
The Clinical Problem Solvers
515 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
370 Listeners
Medicine and the Machine
61 Listeners
Keeping Current CME
28 Listeners
Cardionerds: A Cardiology Podcast
426 Listeners
The Curious Clinicians
374 Listeners
Huberman Lab
29,185 Listeners
Not Otherwise Specified
65 Listeners